Gilead Sciences

Gilead Sciences, Inc., based in Foster City, California, is a premier, research-based biopharmaceutical company renowned for its bold approach to discovering, developing, and commercializing innovative medicines in areas of massive unmet medical need. Since its founding in 1987, Gilead has been a global leader in virology, single-handedly transforming the treatment landscapes for some of the world’s most deadly infectious diseases.

The company is best known for its revolutionary antiviral therapeutics, having developed highly effective, single-pill regimens that turned HIV from a fatal diagnosis into a manageable chronic condition (e.g., Biktarvy, Descovy). Furthermore, Gilead achieved a historic medical milestone by curing Hepatitis C (HCV) with its groundbreaking drugs Sovaldi and Harvoni, functionally eradicating the virus in millions of patients worldwide.

Beyond virology, Gilead has strategically aggressively expanded its footprint into oncology and immunology. Through the landmark acquisition of Kite Pharma, Gilead established itself as a pioneer and global leader in cell therapy, delivering customized, life-saving CAR-T treatments like Yescarta and Tecartus for hematological malignancies. The company is also rapidly advancing a robust portfolio of targeted oncology therapies and antibody-drug conjugates (ADCs) for solid tumors, such as Trodelvy.

Gilead operates highly specialized manufacturing facilities around the globe, ensuring the safe and scalable production of both small molecules and complex biological therapies. Driven by a profound commitment to global health equity, Gilead implements extensive access programs in developing nations, ensuring that its life-saving innovations reach vulnerable populations. With an expansive, cutting-edge clinical pipeline and strategic academic collaborations, Gilead continues to push the boundaries of science to cure life-threatening diseases.